Geode Capital Management
KROS icon

Geode Capital Management’s Keros Therapeutics KROS Stock Holding History

Geode Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.47M Sell
510,841
-170,619
-25% -$1.9M ﹤0.01% 2865
2026
Q1 		$7.52M Buy
681,460
+46,252
+7% +$714K ﹤0.01% 2530
2025
Q4 		$12.9M Sell
635,208
-202,155
-24% -$3.55M ﹤0.01% 2271
2025
Q3 		$13.2M Buy
837,363
+8,066
+1% +$119K ﹤0.01% 2243
2025
Q2 		$11.1M Buy
829,297
+23,112
+3% +$312K ﹤0.01% 2295
2025
Q1 		$8.22M Buy
806,185
+40,749
+5% +$473K ﹤0.01% 2412
2024
Q4 		$12.1M Buy
765,436
+39,815
+5% +$2.07M ﹤0.01% 2246
2024
Q3 		$42.1M Buy
725,621
+46,041
+7% +$2.27M ﹤0.01% 1529
2024
Q2 		$31.1M Buy
679,580
+83,734
+14% +$4.5M ﹤0.01% 1680
2024
Q1 		$39.5M Buy
595,846
+85,635
+17% +$5.08M ﹤0.01% 1511
2023
Q4 		$20.3M Buy
510,211
+24,210
+5% +$759K ﹤0.01% 1916
2023
Q3 		$15.5M Buy
486,001
+65,279
+16% +$2.44M ﹤0.01% 1987
2023
Q2 		$16.9M Buy
420,722
+52,676
+14% +$2.31M ﹤0.01% 1968
2023
Q1 		$15.7M Buy
368,046
+18,298
+5% +$924K ﹤0.01% 1961
2022
Q4 		$16.8M Buy
349,748
+33,599
+11% +$1.57M ﹤0.01% 1891
2022
Q3 		$11.9M Buy
316,149
+41,247
+15% +$1.43M ﹤0.01% 2110
2022
Q2 		$7.59M Buy
274,902
+59
+0% +$2.59K ﹤0.01% 2445
2022
Q1 		$14.9M Buy
274,843
+19,096
+7% +$980K ﹤0.01% 2078
2021
Q4 		$15M Buy
255,747
+42,941
+20% +$2.14M ﹤0.01% 2160
2021
Q3 		$8.42M Sell
212,806
-7,721
-4% -$275K ﹤0.01% 2588
2021
Q2 		$9.37M Buy
220,527
+46,506
+27% +$2.52M ﹤0.01% 2503
2021
Q1 		$10.7M Buy
174,021
+16,561
+11% +$1.05M ﹤0.01% 2319
2020
Q4 		$11.1M Buy
157,460
+47,432
+43% +$2.99M ﹤0.01% 2102
2020
Q3 		$4.24M Buy
110,028
+2,800
+3% +$111K ﹤0.01% 2489
2020
Q2 		$4.02M Buy
+107,228
New +$3.3M ﹤0.01% 2461

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management's KROS Position: Q2 2026 in Review

Geode Capital Management reduced its Keros Therapeutics (KROS) stake by 25% in Q2 2026, selling an estimated $1.9M and leaving 510,841 shares worth $5.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2865.

Geode Capital Management first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $42.1M in Q3 2024. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Geode Capital Management held 510,841 shares of Keros Therapeutics worth $5.47M as of Q2 2026.
  • Geode Capital Management sold 170,619 Keros Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Keros Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2865 holding.
  • Geode Capital Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Keros Therapeutics position peaked at $42.1M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.